Pediatric Heart Network: Trial of BB vs. ARB in Marfan Syndrome

251

Form A200: Adverse Event Form

PHN-06

INSTRUCTIONS: Complete this form each time an adverse event occurs. When an event that was ongoing at the time of initial data entry resolves, then please record all resolution information on another A200 form. Do not update the initial A200 form with resolution information. The Study Coordinator should refer to the CTCAE v.3 booklet, the form QxQ's and Section C.2.6 of the protocol for event definitions and classifications. The Study PI or Clinical Center PI must review and initial this form.

Section A: KEY IDENTIFYING INFORMATION

|     | Occilon A. RETIDE  | THE THE IN CRIMATION  |  |
|-----|--|---|--|
| A1. | Study Identification Number  |   |  |
| A2. | Event number (assigned sequentially by DMS)  |   |  |
| a.  | Form type:   | INITIAL1 (A3) RESOLUTION2   |  |
|     | <ol> <li>Did anything change since the initial form was completed?</li> </ol>  | YES1 <b>(B3)</b> NO   |  |
| A3. | Onset date   | $\frac{1}{M}$ $\frac{1}{M}$ $\frac{1}{D}$ $\frac{1}{D}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ |  |
| A4. | Date form initiated  | $\frac{1}{M}$ $\frac{1}{M}$ $\frac{1}{D}$ $\frac{1}{D}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ |  |
| A5. | Name of person completing form   | PRINT FULL NAME INITIALS  |  |
| A6. | Did this Adverse Event occur during the Musculoskeletal Ancillary Study measurem within 24 hours after measurements were |   |  |
| A7. | Was this event/episode first identified or reported while completing an A116 ADRQ form?  YES                             |   |  |
| a.  | Date of A116 where AE first identified or reported  / /  |   |  |
|     | Section B: DESCRIP   | TION OF ADVERSE EVENT   |  |
| B1. | Is this AE related to a previously reported  | AE? YES1 NO2 <b>(B2)</b>  |  |
| a.  | If YES, specify AE event #   | <del></del>   |  |
| B2. | Event code (CTCAEMedDRAcode)   |   |  |
| a.  | Specify (Event Name per CTCAE Code List)   |   |  |
| a.  | Specify (Event Name per CTCAE Code List)   |   |  |

|     |              |   | Marfa                       | an Trial Subject ID:<br>AF #·                                      |                  |
|-----|--------------|---|-----------------------------|--|------------------|
| B3. |              | Serious Adverse Event   |                             | YES1   | NO2 <b>(B4</b>   |
|     |              | Reason(s) for definition of S   | ERIOUS (Answer              | each question)   |                  |
|     |              |   |                             | YES  | NO               |
| a.  |              | Subject death   |                             | 1  | 2                |
| b.  |              | Life-threatening  |                             | 1  | 2                |
| C.  |              | Required hospitalization or prolonged hospitalization                                 |                             | 1  | 2                |
| d.  |              | Results in persistent/significant incapacity or disruption of normal life functioning |                             | 1  | 2                |
| e.  |              | Results in a congenital anomaly in the offspring of a participant                     |                             | 1  | 2                |
| f.  |              | Important medical event   |                             | 1  | 2                |
| B4. | 00           | verity of event (refer to CTCAI   | _ <b>v</b> o.o <sub>j</sub> | GRADE 1GRADE 2GRADE 3GRADE 4GRADE 5                                | 2<br>3<br>4<br>5 |
| B5. | Expectedness |   | UNEXPECTED1 EXPECTED2       |  |                  |
| B6. | Re           | Relationship to Drug (Causality)  |                             | NOT RELATED<br>POSSIBLY RELATED<br>PROBABLY RELATED                |                  |
|     | a.           | Date last dose of study dru   | ıg taken                    |  | <u> </u>         |
|     | b.           | Time :  | 1. Units                    | AM1 PM   | .2 24 HR3        |
|     | C.           | Study drug action taken   | STUDY DRUG I                | O STUDY DRUGDOSAGE ADJUSTEDDOSAGE TEMPORARILY SPERMANENTLY DISCONT | 2<br>STOPPED     |

| nt of Event<br>ny labs, tests or studie   |              |                      | -           |   |
|---|--------------|----------------------|-------------|---|
|   |              |                      |             |   |
| evaluate this event?  | es done to   | YES                  | 1           | NO2 <b>(B8)</b>                                     |
| of labs, tests or studi   | es done      | (1 -                 | 10)         |   |
| ame   |              | te (mm/dd/yyyy)      | 1c. Resu    | ılt   |
|   | i.           |                      | i.          |   |
|   | ii.          |                      | ii.         |   |
|   | iii.         |                      | iii.        |   |
|   | iv.          |                      | iv.         |   |
|   | V.           |                      | V.          |   |
| subject have any pre-e<br>enditions relevant to the<br>n Marfan Syndrome)?                | is event     |                      | 1           | NO2 <b>(B9)</b>                                     |
| pecify  |              |                      | _           |   |
| Intervention status   |              |                      |             |   |
| aken  |              | YES                  | 1           | NO2 (B10)   |
| Medical Therapy (non-   | drug)        | YES                  | 1           | NO2 ( <b>B9a2</b> )                                 |
| i. If yes, specif   | fy           |                      |             |   |
| 2. Number of Medications administered to treat this AE (0 – 10) <b>If 0, skip to B9a3</b> |              |                      |             |   |
| ment Medication Code ode list D)  | i            |                      |             | e for 99 codes (other)                              |
| i   |              |                      |             |   |
|   |              |                      |             |   |
| ii  |              |                      |             |   |
| iii   |              |                      |             |   |
| iv  |              |                      |             |   |
| lumber of Surgeries o   | r Procedures | performed to treat t | his AE _    | (0- 5) <b>If 0, skip to B</b> 1                     |
| Specify Name of   | of Procedure | Da                   | te of Proce | dure  |
| i   |              | /                    | D D Y       | <del>'</del> <del>Y</del> <del>Y</del> <del>Y</del> |
|   |              | 1                    | /           | - <del>y</del> <del>y</del> <del>y</del>            |
|   | i            |                      | i           | i   |

| Marfan Trial Subject ID:  |                                     |   |        |   |
|---|-------------------------------------|---|--------|---|
| B10. Number   | of medications subject was taking   | at the time of the  |        |   |
| Medication Co<br>(see Code list D   | • •                                 | Start Date (n<br>(If estimated,                                   |        | Stop Date (mm/yyyy) (If estimated, check box. |
| a1  | a2.                                 | a3.   |        | a4.   |
| b1  | b2.                                 | b3.   |        | b4.   |
| c1  | c2.                                 | с3.   |        | c4.   |
| d1  | d2.                                 | d3.   |        | d4.   |
| e1  | e2.                                 | e3.   |        | e4.   |
| b. Re   | RESOLVED RESOLVED  1. Specify:      | G  WITH SEQUELA  D D Y Y  YES  e of death?  PRIMARY  CONTRIBUTING | F1 NO. | 1 <b>(B11b)</b> 22 <b>(B13)</b> 1             |
| <ul> <li>b. Date of Death</li> <li>B13. Did event code from question B2 change?</li> <li>a. Updated event code (CTCAE MedDRA code)</li> </ul> |                                     | UNKNOWN  / / D  YES   | D Y Y  | <u>Y</u> <u>Y</u>                             |
| b. S <sub>l</sub>   | Decify (Event Name per CTCAE Code L | .151)   |        |   |

|   |  | Marfan Trial Subject ID:   |  |  |
|---|--|--|--|--|
|   |  | AE #:  |  |  |
| B14.  | Adverse Event Narrative  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
| B15.  | Date faxed to PHN DCC ase review this form with the Study PI/Clin                          | $\frac{1}{M}$ $\frac{1}{M}$ $\frac{1}{D}$ $\frac{1}{D}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$                              |  |  |
| Cod   | ordinating Center (DCC) for the initial even<br>Study PI/Clinical Center PI must signify t | nt and the resolution.   |  |  |
|   | Initial of PI:   | Date:  |  |  |
| SUBMI   | -  | orting timeframes below based on seriousness of event.   |  |  |
|   | Seriousness  | Reporting Timeframe  |  |  |
| Serious                                       |  | Within 24 hours of first knowledge of event  |  |  |
| Important Medical Event (including pregnancy) |  | Within 24 hours of first knowledge of event  |  |  |
| Not ser                                       | ious   | Within 7 calendar days of first knowledge of event   |  |  |
| Fax all                                       | forms to: AE Medical Monitor PHN Data Coordinating Center Fax number: 617-673-9540         | <b>DATA ENTRY INSTRUCTIONS:</b> This form must be entered into ADEPT as well as faxed to the DCC according to the reporting timeframe above. |  |  |
|   | Section Z: 1   | TIME TO COMPLETE FORM  |  |  |
| Z1.   |  |  |  |  |
|   |  | END OF FORM  |  |  |
|   |  |  |  |  |

| A200 Adverse Event Form | Form A200 | Version D: 01-02-12 | Page 5 of 5 |
|-------------------------|-----------|---------------------|-------------|
|-------------------------|-----------|---------------------|-------------|